Zhao Zichu, Ye Cong, Dong Lingli
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Int Immunopharmacol. 2020 Jun;83:106480. doi: 10.1016/j.intimp.2020.106480. Epub 2020 Apr 10.
Tofacitinib is an oral, small molecule JAK inhibitor that targets JAK1/JAK3. Tofacitinib has been approved by the FDA to be used in the treatments of rheumatoid arthritis, psoriatic arthritis, plaque psoriasis and ulcerative colitis. Considering the important pathogenic role of the JAK/STAT pathway in autoimmune disease, tofacitinib could be, theoretically, effective in the treatments of other systemic rheumatic diseases. Here we reviewed the published literature to profile the perspectives about the off-label uses of tofacitinib, especially in those refractory cases with poor response to conventional therapies or biologic agents. Tofacitinib can be a new therapeutic option and help reducing hormone dependence and correlated adverse events.
托法替布是一种口服小分子JAK抑制剂，作用靶点为JAK1/JAK3。托法替布已获美国食品药品监督管理局（FDA）批准，用于治疗类风湿性关节炎、银屑病关节炎、斑块状银屑病和溃疡性结肠炎。鉴于JAK/STAT通路在自身免疫性疾病中具有重要的致病作用，理论上托法替布可能对其他系统性风湿性疾病的治疗有效。在此，我们回顾了已发表的文献，以概述关于托法替布超说明书用药的观点，尤其是在那些对传统疗法或生物制剂反应不佳的难治性病例中。托法替布可以成为一种新的治疗选择，并有助于减少激素依赖及相关不良事件。
